Side-by-side · Research reference
SemaglutidevsTB-500
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AFDA-ApprovedVerified15/53 cited
BPhase 2Reviewed8/46 cited
Semaglutide
GLP-1 RA · FDA-Approved
SQ · Abdomen / thigh / arm · Once weekly
TB-500
Thymosin β4 fragment · Healing
SQ or IM · Multiple sites · 2–3×/week
01Mechanism of Action
Parameter
Semaglutide
TB-500
Primary target
GLP-1 receptor (GLP-1R)WEGOVY (semaglutide) injection 2021
G-actin (sequestering) + cell-surface integrinsGoldstein 2012
Pathway
GLP-1R agonism → ↑glucose-dependent insulin secretion, ↓glucagon, ↓gastric emptying, ↓appetite via hypothalamic centresWilding 2021
Actin remodelling → cell migration; integrin-linked signaling → angiogenesis; anti-inflammatory cytokine modulationGoldstein 2012Malinda 1999
Downstream effect
Improved glycemic control, reduced caloric intake, body-weight reduction, cardiovascular risk reductionWilding 2021
Accelerated wound healing, endothelial migration, hair follicle regeneration, cardiac repair (preclinical)Goldstein 2012
Feedback intact?
Glucose-dependent insulin release preserves physiological feedback
Endogenous protein at baseline; supplementation amplifies
Origin
Modified GLP-1(7-37) with two amino-acid substitutions and C-18 fatty-acid acylation for albumin binding and 168-h half-lifeWEGOVY (semaglutide) injection 2021
17-AA active fragment of endogenous 43-AA thymosin β4 (TMSB4X gene)Goldstein 2012
Antibody development
—
—
02Dosage Protocols
Parameter
Semaglutide
TB-500
Standard dose (weight, Wegovy)
2.4 mg / week (after 16-wk titration)WEGOVY (semaglutide) injection 2021Wilding 2021
—
Frequency
Once weekly, same day each week
2× per week (loading); then 1× per week (maintenance)
Titration schedule
0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16 weeks
Mitigates GI side effects.
—
Evidence basis
FDA-approved · Phase 3 RCTsWilding 2021WEGOVY (semaglutide) injection 2021
Animal-strong + Phase 2 dermal/ocular trialsGoldstein 2012
Duration
Indefinite for chronic indication
Discontinuation results in weight regain.
4–8 weeks loading; longer maintenance for chronic injury
Reconstitution
Pre-mixed pen device (commercial). Research lyophilised vial: bacteriostatic water per label.
Bacteriostatic water, 1–2 mL per 5 mg vial
Timing
Any time of day, with or without food
Evening or pre-rest preferred (anecdotal)
Half-life
~7 days (168 h)WEGOVY (semaglutide) injection 2021
~2 hours (estimated; tissue uptake longer)
Standard dose
—
2 mg per injectionGoldstein 2012
Anecdotal community range; clinical Phase 2 trials used 70–840 mcg/kg IV.
Lower / starter dose
—
1 mg per injection
04Side Effects & Safety
Parameter
Semaglutide
TB-500
GI symptoms
Nausea, vomiting, diarrhea, constipation (very common)Wilding 2021
Rare nausea (anecdotal)
Injection site reaction
Mild erythema, pruritus
Mild erythema, transient pain
Thyroid C-cell tumours
Boxed warning — contraindicated in MEN2 / personal or family MTC historyWEGOVY (semaglutide) injection 2021
—
Hypoglycemia
Low risk as monotherapy; elevated when combined with sulfonylureas / insulin
—
Gallbladder events
Increased cholelithiasis
—
Heart rate
Modest ↑ resting HR (~2-4 bpm)
—
Cancer risk
—
Theoretical via angiogenesis pathway
Lethargy / fatigue
—
Reported anecdotally during loading phase
Antibody formation
—
No data (no long-term human trials)
Long-term safety
—
Unknown beyond Phase 2
Absolute Contraindications
Semaglutide
- ·Personal or family history of medullary thyroid carcinoma
- ·Multiple endocrine neoplasia syndrome type 2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to semaglutide
TB-500
- ·Active malignancy (theoretical angiogenesis concern)
- ·Pregnancy / breastfeeding
Relative Contraindications
Semaglutide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Diabetic retinopathy (may worsen with rapid glycemic improvement)
TB-500
- ·Cancer history
- ·Concurrent VEGF inhibitor therapy
05Administration Protocol
Parameter
Semaglutide
TB-500
1. Reconstitution / device
Commercial: pre-filled pen, no reconstitution. Research vial: per-label or bacteriostatic water.
Add 1–2 mL bacteriostatic water to 5 mg vial → 2.5–5 mg/mL. Roll gently.
2. Injection site
SQ — abdomen, thigh, or upper arm. Rotate sites weekly to avoid lipohypertrophy.
SQ near injury site (preferred), or systemic SQ (abdomen). Rotate sites.
3. Timing
Once weekly, same day. Day can be changed if ≥2 days separate doses.
Evening or pre-sleep is most common anecdotal timing.
4. Storage
Pen: refrigerate 2–8 °C unopened; room temp ≤30 °C up to 56 days after first use.
Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.
5. Needle
Pen-supplied 31–34G needle. Research vial: 27–31G insulin syringe.
27–31G, 4–8 mm insulin syringe.
06Stack Synergy
Semaglutide
+ Tirzepatide
WeakCombining two GLP-1 RA-class drugs is not clinically validated and risks additive GI toxicity. Tirzepatide's GIP component already provides complementary mechanism vs pure GLP-1; stacking with semaglutide adds receptor saturation but no synergy. NOT recommended.
- Note
- Stack not recommended — choose one GLP-1 RA
- Primary benefit
- (none — additive toxicity, no synergy)
TB-500
+ BPC-157
StrongTB-500 and BPC-157 cover complementary halves of tissue repair: BPC-157 upregulates VEGFR2-driven angiogenesis and fibroblast outgrowth; TB-500 sequesters G-actin to enable endothelial / epithelial migration. The anecdotal canonical "healing stack" — pairs especially well for tendon and ligament injuries.
- TB-500
- 2 mg SQ · 2× per week
- BPC-157
- 250–500 mcg SQ · daily
- Primary benefit
- Combined angiogenesis + cell migration for tendon/ligament/muscle repair